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Streptococcus mutans (SM), a major pathogen of dental caries, may promote 25 
systemic infections after accessing the bloodstream from oral niches. In this study, we 26 
investigate pathways of complement immunity against SM, and show that the orphan 27 
regulator CovRSm modulates susceptibility to complement opsonization and survival in 28 
blood. SM blood isolates showed reduced susceptibility to C3b deposition compared to 29 
oral isolates. Reduced expression of covRSm in blood strains was associated with 30 
increased transcription of CovRSm-repressed genes required for SM interaction with 31 
glucan (gbpC, gbpB and epsC), sucrose-derived exopolysaccharides (EPS). Consistently, 32 
blood strains showed increased capacity to bind glucan in vitro. Deletion of covRSm in 33 
strain UA159 (UAcov) impaired C3b deposition and binding to serum IgG and C-34 
reactive protein (CRP) as well as phagocytosis through C3b/iC3b receptors and killing 35 
by neutrophils. Opposite effects were observed in mutants of gbpC, epsC or gtfB/C/D 36 
(required for glucan synthesis). C3b deposition on UA159 was abolished in C1q-37 
depleted serum, implying that the classical pathway is essential for complement 38 
activation on SM. Growth in sucrose-containing medium impaired binding of C3b and 39 
IgG to UA159, UAcov and blood isolates, but had absent or reduced effects on C3b 40 
deposition in gtfB/C/D, gbpC and epsC mutants. UAcov further showed increased ex 41 
vivo survival in human blood in an EPS-dependent way. Consistently, reduced survival 42 
was observed in the gbpC and epsC mutants. Finally, UAcov showed increased ability 43 
to cause bacteremia in a rat model. These results reveal that CovRSm modulates 44 

















Streptococcus mutans (SM) is a common species of the oral cavity of humans 49 
involved in the pathogenesis of dental caries, which can promote infective endocarditis 50 
and other systemic infections after gaining access to the bloodstream (1,2-4). Factors 51 
involved in SM survival in the bloodstream are however unknown, but likely include 52 
mechanisms to evade host immunity. SM expresses the orphan response regulator 53 
CovRSm (also known as GcrR) (5-8), which is an orthologue of the CovR protein of the 54 
two-component regulatory system (TCS) CovRS (also known as CsrRS) of the 55 
pathogenic species Streptococcus pyogenes (group A Streptococcus, GAS) and 56 
Streptococcus agalactiae (group B Streptococcus, GBS). In GAS, CovRSpy typically 57 
functions as a repressor of a panel of virulence genes involved in evasion of host 58 
immunity and tissue invasiveness (9). In SM, CovRSm represses virulence factors 59 
involved in the establishment of SM in dental biofilms (7,8,10,11) but its role in 60 
systemic virulence is unknown. Genes directly repressed by CovRSm include gtfB and 61 
gtfC, which encode glucosyltransferases B and C required for the extracellular 62 
synthesis of glucan from sucrose (7), major structural exopolysaccharides (EPS) of 63 
cariogenic biofilms (1,2). CovRSm also inhibits expression of several genes involved in 64 
cell wall biogenesis and surface interactions with EPS, including GbpB (glucan-binding 65 
protein B), GbpC (glucan-binding protein C), EpsC (enzyme for exopolysaccharide 66 
synthesis: UDP-N_Acetylglucosamine 2-Epimerase), LysM (lysine motif protein) and 67 
WapE (cell wall protein E) (8,10-12). 68 
An isogenic mutant of covRSm obtained in UA159 (serotype c) shows impaired 69 
susceptibility to phagocytosis by human PMN in a blood-dependent manner (13). 70 
Among the four known SM serotypes (c, e, f, and k), serotype c is the most prominent 71 
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in the oral cavity (approximately 70 to 80% of the strains), and is frequently associated 72 
with systemic infections, being detected in 30.3 and 65.5% of SM-positive specimens 73 
of cardiac valve and atheromatous plaque from patients subjected to cardiac surgeries 74 
(14,15). The serotype c strain MT8148 survives during 1 to 2 days in the bloodstream 75 
of rats (16), further suggesting mechanisms of evasion of blood immunity. In this 76 
study, we investigated the roles of CovRSm in susceptibility of SM strains to 77 
complement immunity mediated by C3b, a major opsonin present in blood and other 78 
host fluids (17,18). Profiles of C3b deposition were compared between strains isolated 79 
from blood of patients with bacteremia and/or infective endocarditis and from the oral 80 
cavity, to assess diversity in susceptibility to complement immunity. Low susceptibility 81 
to C3b deposition observed in blood isolates was then compared to transcript levels of 82 
covRSm and of CovRSm-repressed genes. Effects of covRSm deletion in strain UA159 83 
(serotype c) on binding of C3b, IgG antibodies and C-reactive protein (CRP), and on 84 
phagocytosis mediated by C3b/iC3b or IgG receptors and killing by human neutrophils 85 
(PMN) were determined. Mechanisms of CovRSm-regulation of SM susceptibility to 86 
complement immunity were then investigated by assessing the effects of deletion of 87 
CovRSm-regulated genes (gtfB, gtfC, gbpC, epsC, lysM and wapE) on C3b- and antibody-88 
mediated immunity in the presence or absence of sucrose-derived EPS. Finally, strains 89 
were compared regarding ex vivo survival in human blood and in a rat model of 90 


















MATERIAL AND METHODS 96 
 97 
Studied strains and culture conditions.  Strains used in this study are described in 98 
Table 1.(11,13,19-22)Strains  were  grown  (37°C; 10% CO2) from frozen stocks in Brain Heart 99 
Infusion (BHI) agar (Difco).  BHI or chemically defined medium (CDM) (10) with or 100 
without sucrose (0.01 and 0.1%) were used in the experiments. Erythromycin (10 101 
μg/ml), spectinomycin (200 μg/ml) and/or kanamycin (500 μg/ml) (Merck Labs, 102 
Germany) were added to media for cultivation of deletion and complemented 103 
mutants, respectively.  104 
 105 
Construction of gbpC  deletion and complemented mutants. The nonpolar gbpC 106 
deletion mutant was obtained in strain UA159 (UAgbpC) by double cross-over 107 
recombination with a null allele (of 2,315 pb) constructed by PCR-ligation (23). In the 108 
recombinant allele, an internal sequence of 1,455 bp of gbpC encoding region was 109 
replaced by an erythromycin resistance cassette (ermr) obtained from plasmid pVA838. 110 
Complemented gbpC mutant (UAgbpC+) was obtained by transforming UAgbpC with 111 
plasmid pDL278 containing the intact copy of gbpC and spectinomycin resistance gene. 112 
Primers used for construction of mutants are depicted in Table 2.  113 
 114 
RNA isolation, reverse transcription and qPCR.  RNA was purified from strains at mid-115 
log phase of growth (A550nm 0.3) using RNeasy kit (Qiagen, Germany) and treated with 116 
Turbo DNase (Ambion, USA), as described elsewhere (11). The cDNA was obtained 117 
from 1 μg of RNA using random primers (24) and SuperScript III (Life Technologies, 118 
USA), according to the manufacturer's instruction. Quantitative PCR was performed in 119 
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StepOne™ Real-Time PCR System (Life Technologies) with cDNA (10 ng), 10 μM of each 120 
primer, and 1× Power SYBR® Green PCR Master Mix (Lifetech) in a total volume of 10 121 
μl. The cycling conditions were:  95 °C for 10 min, followed by 40 cycles of 95 °C for 15 122 
s, optimal temperature for primer annealing (Table 2) for 15 s, and 72 °C for 30 s. Ten-123 
fold serial dilutions of genomic DNA (300 ng to 0.003 ng) were used to generate 124 
standard curves for absolute quantification of RNA expression levels. Melting curves 125 
were obtained for each primer set. Results were normalized against SM 16SrRNA gene 126 
expression (24). Assays were performed in duplicate with at least two independent 127 
RNA samples. 128 
 129 
SM interaction with EPS. Cell aggregation mediated by sucrose-derived EPS was 130 
assessed as described previously (25). Briefly, strains were grown in BHI (37°C; 10% 131 
CO2, 18 h) and an equal number of cells was transferred to fresh BHI supplemented 132 
with 0.1% sucrose and incubated for 24 h (37°C; 10% CO2). Cell aggregation was then 133 
visually inspected.  134 
Surface-associated EPS was analyzed by scanning electron microscopy (SEM) in 135 
strains  grown in BHI or CDM with or without 0.1% sucrose. Briefly, overnight cultures 136 
obtained in BHI or CDM medium were 100-fold diluted with fresh medium containing 137 
or not 0.1% sucrose, and incubated to reach A550nm 0.3.  Cells were then harvested by 138 
centrifugation (500 µl), washed with phosphate-buffered saline (PBS), and processed 139 
for SEM analysis, as previously described (12). Samples were analyzed with a scanning 140 















Volunteers, sera and blood samples.  Blood samples were collected by 143 
venipuncture  in heparin vacuum tubes (BD Vacutainer®) from six healthy subjects 144 
(three males, three females; mean age: 30 years, range 25 to 45 years), according to 145 
standard protocols previously approved by the Ethical Committee of the Piracicaba 146 
Dental School, State University of Campinas (proc. nº 031/2012). Serum samples were 147 
stored in aliquots at -70 oC until use.  Levels of C3 were determined in serum samples 148 
as described below, and were within normal levels in all volunteers (mean 1.91 mg/ml; 149 
SD 0.68; range 1.18 to 2.88 mg/ml) (26). Mean levels of IgG and IgM immunoglobulins 150 
were also determined in the same samples and were, respectively, 11.68 mg/ml (± 151 
1.82) and 1.35 mg/ml (± 0.64). Serum samples from one volunteer, which were 152 
representative of C3, IgG and IgM levels were used as control. Commercial human 153 
serum depleted of C1q, was obtained from Calbiochem, MA, U.S.A.. The  Calbiochem 154 
C1q-depleted serum is free of EDTA and retains alternative pathway activity (27). As a 155 
control for integrity, C1q-depleted serum was supplemented with purified human C1q 156 
(Calbiochem) to a physiological concentration range (75 µg/ml  in 100% serum).  Heat-157 
inactivated sera (56 oC for 20 min) were also used as negative controls in preliminary 158 
experiments, and showed minimal effects on comparative analyses of C3b deposition 159 
between strains.  160 
 161 
Determination of total levels of C3, IgG and IgM antibodies in serum. The serum 162 
concentrations of C3, IgG and IgM antibodies were determined in enzyme-linked 163 
immunosorbent assays (ELISA) using commercial systems for quantification of human 164 
complement C3 (Molecular® Innovations, MI, U.S.A.), human IgG or human IgM (Bethyl 165 
Laboratories, Inc., TX, U.S.A.), respectively. Briefly, 100 µl of serum samples diluted in 166 
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dilution buffer (1:100,000; 1:500,000 and 1:10,000, respectively) were added to 96-167 
well plates coated with anti-C3, anti-IgG or anti-IgM immunoglobulins, then incubated 168 
for 30 min at room temperature (rt). After a series of three washes with wash buffer, 169 
100 µl aliquots of antibodies specific to C3, human IgG, or human IgM were added per 170 
well, and plates incubated (rt) for 1 h. After a new series of washes, 100 µl per well of 171 
secondary horseradish peroxidase (HRP)-conjugated antibodies (1:50,000) were 172 
added, and incubation continued for 30 min. After a new series of washes, 100 µl per 173 
well of chromogenic HRP substrate (3,3',5,5'-tetramethylbenzidine) were added and 174 
plates incubated for 30 min. Reactions were stopped by addition of 1 N H2SO4. 175 
Absorbances (A450nm) were measured in a microtiter plate reader (Versa Max®), and 176 
converted to mg/ml using standard curves of C3 (0.02 - 10 ng/ml), IgG (0.69 - 167 177 
ng/ml) or IgM (1.03 - 250 ng/ml) antibodies.     178 
 179 
C3b deposition on SM. Deposition of C3b on the surface of serum-treated SM strains 180 
was determined as described elsewhere (27,28), with some modifications. Briefly, 181 
approximately 107 cfu of strains at mid-log phase of growth (A550nm 0.3) were harvested 182 
by centrifugation (10,000 x g, 4oC), washed two times with PBS (pH 7.4) and suspended 183 
in 20 µl of 20% serum (diluted in PBS).  Samples were then incubated (37oC; 30 min) 184 
and washed twice with PBS-Tween 0.05% (PBST). Then, cells were incubated on ice (40 185 
min) with fluorescein isothiocyanate (FITC)-conjugated polyclonal goat anti-human C3 186 
IgG antibody (ICN, CA, U.S.A) (1:300 in PBST). After two washes with PBST, bacterial 187 
cells were fixed in 3% paraformaldehyde in PBS and analyzed on a FACSCalibur flow 188 
cytometer (BD Biosciences) using forward and side scatter parameters to gate at least 189 
25,000 bacteria. Results were expressed as the geometric mean fluorescence intensity 190 
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(MFI) of C3b-positive cells or as mean fluorescence index (FI; percentage of positive 191 
cells multiplied by the MFI) (29,30). Control samples included bacteria treated only 192 
with PBS instead of serum.  193 
 194 
PMN isolation, opsonophagocytosis and killing assays.  Human PMN were isolated 195 
from fresh heparinized blood samples from one reference volunteer by centrifugation 196 
over a double gradient composed of 1119 and 1083 density Histopaque (Sigma-197 
Aldrich), as previously described, with modifications (31). Red blood cells were 198 
eliminated by hypotonic lysis. Isolated PMN were suspended in RPMI 1640 (GIBCO®, 199 
Life Technologies, NY, USA) medium supplemented with inactivated 10% fetal bovine 200 
serum. Cell viability (>98%) was monitored by trypan blue exclusion. Cell purity (>95%) 201 
was monitored by May-Grunwald Giemsa staining. 202 
For the opsonophagocytosis assays, bacteria were previously labeled with FITC 203 
as described elsewhere (32), with some modifications. Briefly, 500 µl of bacterial 204 
strains (A550nm 0.3) were washed two times with PBS, suspended in 600 µl of carbonate 205 
buffer (Na2CO3 0.15 M, 0.9% NaCl; pH 9) with 1.7 mg/ml of FITC (Sigma), and incubated 206 
for 1 h (shaking at rt in the dark). Then, cells were harvested and washed three times 207 
with PBST, and aliquots stored overnight in 10% glycerol at -70oC. Bacterial labeling 208 
was analyzed in a fluorescent microscope (Leica DM LD), and by flow 209 
cytometry (FACSCalibur, BD). 210 
For C3b deposition, aliquots containing 107 cfu of FITC-labeled bacteria were 211 
incubated with 20% serum and added to wells of 96-well plates containing 2 x 105 PMN 212 
in 50 µl of RPMI medium to a multiplicity of infection (MOI) of 200 bacterial per PMN. 213 
After incubation (37oC, 10% CO2, gentle shaking) for 5 or 30 min, reactions were fixed 214 
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by addition of 100 µl of 3% of paraformaldehyde.  PMNs were then analyzed using 215 
FACSCalibur (BD Biosciences), and the frequency of phagocytosis expressed as the 216 
number of PMN cells with intracellular bacteria, within a total of 10,000 PMN analyzed 217 
(33). The MOI was determined in preliminary experiments testing MOIs of 20 to 200 218 
bacteria per PMN, after 5 to 60 min of incubation. Flow cytometry analysis was 219 
compared to light microscopy analysis of samples stained using May-Grunwald-220 
Giemsa, as previously described (13). These comparisons confirmed that most of PMN-221 
associated bacteria were internalized. 222 
To assess phagocytosis by PMN through C3b/iC3b receptors, similar assays 223 
were performed with PMN previously incubated (37°C, 30 min) with mouse 224 
monoclonal antibodies (MAbs) anti-CD35 (Biolegend, CA, U.S.A.) or anti-CD11b/CD18 225 
to block CR1 or CR3 receptors (34,35), respectively. As reference, PMN incubated with 226 
MAbs anti-CD32 (FcγRII) (eBioscience,CA, U.S.A.) or anti-C16 (FcγRIII) (Biolegend, CA, 227 
U.S.A.) were also tested.  228 
Opsonophagocytic killing was assessed as previously described (36,37), with 229 
modifications. Briefly, preopsonized bacteria (20% human serum for 30 min at 37°C) 230 
were added to samples of human PMN in RPMI with 10% human serum at the MOI 231 
200:1. After incubation (37°C; 10 and 30 min) under shaking, reactions were stopped 232 
at 4°C. PMN were harvested by centrifugation (500 x g; 8 min, 4°C), washed twice with 233 
PBS (pH 7.2), lysed with 2% saponin (12 min, 37°C) and viable counts of intracellular 234 
bacteria determined by plating serial dilutions on BHI agar. Bacterial counts were also 235 
determined in control wells with identically treated samples without PMN. Viable 236 
bacteria were counted in culture supernatants of PMN samples to monitor the number 237 
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of extracellular bacteria. Percentage of intracellular survival was calculated as follows: 238 
(cfu ml-1 test well)/cfu ml-1 control well) x 100. 239 
 240 
Determination of binding of serum IgG, IgM and CRP to SM. Binding of serum IgG, 241 
IgM or CRP to SM was determined as previously described (27,38) with some 242 
modifications. Briefly, bacterial strains were harvested from 500 µl of  cultures of 243 
UA159 (A550nm 0.3), washed twice with PBS (pH 7.0), incubated with 20% serum, and 244 
washed with PBST. To assess surface levels of IgG, IgM or CRP, cells were then 245 
incubated with polyclonal goat IgG anti-human IgG Fc conjugated with FITC (Novus 246 
Biological, U.S.A.) (1:900), with polyclonal mouse IgG anti-human IgM Fc conjugated 247 
with allophycocyanin (APC) (1:1000) (Biolegend, U.S.A.) or with goat IgG anti-human 248 
CRP conjugated with FITC (GeneTex, U.S.A.) (1:100), respectively. Streptococcus 249 
pneumoniae strains D39 and TIGR4 were used as controls for CRP binding, because S. 250 
pneumoniae cell wall contains known CRP ligands (phosphorylcholine; PCho) (39).   251 
After 40 min incubation on ice, bacterial cells were washed twice with 300 µl of PBST, 252 
harvested (16,000 x g, 2 min) and suspended in 300 µl of 3% of paraformaldehyde. 253 
Flow cytometry analyses were performed as described before, using forward and side 254 
scatter parameters to gate at least 25,000 bacteria. Bacterial samples treated with PBS 255 
instead of serum were used as negative controls. 256 
 257 
Ex vivo survival of SM strains in human blood. Bacteria from BHI cultures (A550nm 0.3) 258 
were harvested (11,000 x g, 2 min), washed twice in PBS, and resuspended in 1 ml of 259 
fresh whole human blood. Samples were then incubated (37oC, 5% CO2, gentle 260 
agitation), and aliquots collected at different time points (5, 30, 60, 120, 240 min), 261 
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serially diluted and plated on BHI agar for determination of bacterial counts. Aliquots 262 
collected just after bacterial suspension in blood were used for initial measure of 263 
cfu/ml (time 0). Changes in numbers of viable bacteria were then calculated in relation 264 
to counts at time 0, to reduce the influence of variations in blood-mediated 265 
aggregation between strains on the numbers of cfu/ml. Three independent 266 
experiments were performed in duplicate with blood samples from one volunteer with 267 
reference levels of C3, IgG, and IgM (2.8, 14.6, 1.5 µg/ml of serum, respectively).   268 
 269 
Survival of SM strains in a rat model of bacteremia and infective endocarditis. 270 
Protocols of the animal experiments were approved by the institutional animal care 271 
and use committee of Osaka University Graduate School of Dentistry (No. 24-019). 272 
Animals were maintained and handled in accordance with guidelines for animal 273 
research. The rat infective endocarditis model was performed according to methods 274 
described previously, with some modifications (40). In brief, 21 Sprague-Dawley male 275 
rats (400-500 g each) were anesthetized with a mixture of xylazine and midazolam (0.1 276 
ml/100 g). A sterile polyethylene catheter with a guide wire was surgically placed 277 
across the aortic valve of each animal via the right carotid artery, and the tip was 278 
positioned and placed at the aortic valve in the left ventricle. Bacterial suspension (109 279 
cells per body, from BHI cultures) in PBS was intravenously administered through the 280 
jugular vein. Bacterial clearance was examined by measuring the numbers of bacteria 281 
in blood samples from the jugular veins, which were taken at 1, 3, 6, and 24 h, and 7 282 
days after the initial infection. The blood samples were placed on Mitis-salivarius agar 283 
(Difco Laboratories, Detroit, MI, USA) plates containing bacitracin (0.2 U/ml; Sigma 284 
Chemical Co., St. Louis, MO, USA) and 15% (wt/vol) sucrose (MSB agar) and incubated 285 
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at 37°C for 48 h.  Seven days after bacterial infection, the rats were sacrificed by an 286 
overdose of anesthesia and the aortic valves were extirpated, transversely sectioned, 287 
and subjected to Gram staining and to bacterial recovery for microbial counting. 288 
 289 
Statistical analyses. Flow cytometry data (percentage of positive bacteria or PMN, and  290 
MFI or FI values) were analyzed by comparing means of at least three independent 291 
experiments, using nonparametric Kruskal-Wallis test with Dunns’s post hoc test. 292 
Comparisons of the mean MFI or FI for surface-bound C3b between oral and blood 293 
isolates were performed using Mann-Whitney U-test. Spearman’s rank correlation was 294 
applied to analyze associations between MFI of surface C3b and surface IgG. Ex vivo 295 
survival in blood was compared between strains by testing differences in relative 296 
values of bacterial counts (log of cfu/ml) at each time point of incubation in relation to 297 
initial counts in blood suspensions. Bacterial counts in the rat bloodstream were also 298 
compared between strains. Relative or absolute measures of bacterial counts were 299 
compared between strains at each time-point using Kruskal-Wallis with post hoc 300 




SM strains isolated from blood show reduced susceptibility to C3b deposition 305 
compared to oral isolates. Although complement immunity is recognized as an 306 
important blood defense against streptococcal species (18,28,41), the profiles of SM 307 
susceptibility to complement-mediated opsonization were unknown. Thus, we 308 
compared patterns of C3b deposition on strains isolated from the bloodstream of 309 
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patients with bacteremia associated or not with infective endocarditis (n = 7), and 310 
isolates of the oral cavity (n = 13), including the reference strain UA159. As shown in 311 
Fig. 1, blood isolates showed reduced levels of C3b deposition compared to oral 312 
isolates. Two blood serotype c strains (SA13 and SA18) showed the lowest MFI for C3b 313 
(mean MFI: 148.9 ± 65.8 and 215.7 ± 112.0, respectively), and low FI (mean FI: 2,069.0 314 
± 802.8 and 3,019.9 ± 1,056.4, respectively). Means of MFI and FI of strain UA159 were 315 
623.2 (± 100.3) and 17,678.4 (± 2,908.7), respectively.  316 
 317 
SM blood strains show reduced activity of covRSm and increased 318 
transcription of CovRSm-target genes required for surface interaction with EPS. To 319 
investigate the role of CovRSm on strain susceptibilities to C3b deposition, transcript 320 
levels of covRSm and downstream genes were compared between four blood strains 321 
showing the lowest levels of C3b deposition (SA13, SA15, SA16 and SA18) with four 322 
oral isolates with the highest levels of binding to C3b (2VS1, 11A1, 11SSST2 and 8ID3), 323 
and the reference strain UA159. The CovRSm-repressed genes selected were those 324 
affecting SM cell surface properties, including lysM, wapE, epsC, gbpB, gbpC, gtfB, 325 
gtfC, and gtfD (glucosyltransferase D encoding gene) (7,11,42). As shown in Fig. 2, 326 
blood strains showed lower levels of covRSm transcripts than the oral isolates. 327 
Consistently, blood isolates showed increased transcription of epsC, gbpC, and gbpB, 328 
genes involved in SM surface interaction with EPS (11,12,43). No significant differences 329 
in transcript levels of lysM, wapE, gtfB, gtfC or gtfD were detected (Fig. 2). Levels of 330 
C3b deposition in the analyzed strains negatively correlated with transcript levels of 331 
epsC (Spearman correlation: r: -0.45, p<0.05), gbpB (r: -0.21, p<0.05) and gbpC (r: -332 
0.35, p<0.05). Thus, diversity in transcriptional activities of covRSm and of CovRSm-333 
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repressed genes are associated with differences in levels of C3b deposition in SM  334 
strains.  335 
 336 
SM blood strains show increased capacity to bind EPS produced in the 337 
presence of sucrose, similarly to the covRSm isogenic mutant. Because gbpB, gbpC and 338 
epsC encode proteins for SM binding to sucrose-derived EPS (glucan) (11,12,43), we 339 
compared the capacities of aggregation in the presence of sucrose between blood and 340 
oral isolates. Isogenic mutants of covRSm and of CovRSm-repressed genes (gbpC, epsC, 341 
gtfB, gtfC, lysM, wapE) were also tested, except for gbpB, which is essential for SM 342 
viability (12). As shown in Fig. 3A, blood isolates showed higher capacity to aggregate 343 
in 0.1% sucrose BHI medium, compared to oral isolates. The blood strains SA13 and 344 
SA18 showed aggregation phenotypes similar to that of UAcov strain (Fig 3B). As 345 
anticipated, the gbpC isogenic mutant did not aggregate, while only weak aggregation 346 
was detected in the epsC mutant (Fig. 3C). In addition, because gtfB, gtfC and gtfD are 347 
required for the synthesis of glucan from sucrose, mutants of these genes obtained in 348 
strain MT8148 did not aggregate (Fig. 3C). The aggregation phenotypes of the gbpC 349 
mutants obtained in MT8148 (Fig. 3C) and in UA159 (Fig. 3B) were similar. SEM 350 
analysis supported previous report (11) on the increased interaction of UAcov with 351 
sucrose-derived EPS in biofilms, and confirmed strain capacities to bind sucrose-352 
derived EPS under the growth conditions applied in the C3b binding assays (data not 353 
shown).  354 
 355 
Inactivation of covRSm impairs deposition of C3b, phagocytosis mediated by 356 
C3b/iC3b receptors and opsonophagocytic killing by human PMN. UAcov shows low 357 
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susceptibility to phagocytosis by human PMN in a serum-dependent way (13), 358 
suggesting that CovRSm regulates surface components affecting serum opsonization. As 359 
shown in Fig. 4A, deposition of C3b was impaired in UAcov. This phenotype was 360 
completely restored in the complemented mutant UAcov+. Significant reductions in 361 
the frequencies of phagocytosis of UAcov in the presence of 20% serum were also 362 
observed in comparison to parent UA159 or UAcov+ (Fig. 4B). Importantly, blocking of 363 
CR1 and/or CR3 receptors of PMN with anti-CD35 (CR1) or anti-CD11b/CD18 (CR3) 364 
antibodies reduced differences in the frequencies of phagocytosis between UA159 and 365 
UAcov (Fig. 4B). Additionally, simultaneous blockage of CR1 and CR3 receptors 366 
abolished differences in the frequencies of phagocytosis between these strains (Fig. 367 
4B), reflecting the multiple and cooperative functions of CR1 and CR3 on bacterial 368 
phagocytosis mediated by C3b/iC3b (44). PMN treatment with anti-CD32 (FcɤRII) or 369 
anti-CD16 (FcɤRIII) antibodies also reduced phagocytosis of UA159, although blockage 370 
of both Fcɤ receptors did not eliminate differences in the frequencies of phagocytosis 371 
between UA159 and UAcov (Fig. 4B). 372 
To examine if reduced phagocytosis of UAcov was associated with reduced 373 
killing by PMN, strains were compared in opsonophagocytic killing assays. As shown in 374 
Fig. 4C, UAcov showed increased survival to PMN killing during 10 min of incubation. 375 
Similar results were obtained after PMN exposure to the tested strains during 30 min 376 
(data not shown). Viable bacteria in PMN culture supernatants were monitored, 377 
confirming reduced phagocytosis of UAcov compared to UA159; mean counts of UAcov 378 
in culture fluids were significantly higher than UA159 counts (p<0.05). These data 379 
establish the strong influence of C3b/iC3b deposition on SM phagocytosis and imply 380 
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that reduced deposition of C3b/iC3b on UAcov not only impairs phagocytosis mediated 381 
by C3b/iC3b receptors, but is associated with reduced killing by PMN.   382 
 383 
C3b deposition on SM is strongly dependent of C1q of the classical pathway 384 
of complement activation. We hypothesized that EPS bound to SM surface could 385 
compromise antibody recognition of immunogenic surface proteins, thus affecting the 386 
classical pathway of complement activation. In this pathway, proteolytic cascade 387 
initiates with C1q binding to different host components bound to the bacterial surface, 388 
most prominently IgG or IgM antibodies, but also acute-phase proteins of the innate 389 
immunity, e.g. CRP (17,18). Therefore, we analyzed the effect of covRSm inactivation on 390 
levels of antibodies bound to SM (from pools of sera from six volunteers), and 391 
investigated the effect of the classical pathway on binding of C3b to SM. Because the 392 
classical pathway can be also activated by CRP bound to the surface of streptococcal 393 
species containing CRP ligands (27,45), we additionally assessed binding of this acute-394 
phase protein to SM. As shown in Fig. 5A, significant reductions in binding of IgG 395 
antibodies were observed in UAcov, compared to parent strain. In addition, although  396 
levels of CRP bound to SM UA159 were low, compared to the S. pneumoniae control 397 
strains, UAcov showed reduced binding to CRP compared to UA159 (Fig. 5B). 398 
Importantly, levels of surface-bound IgG and CRP were restored in the complemented 399 
mutant UAcov+ (Fig. 5A,B). No significant changes in binding of IgM antibodies to SM 400 
were observed (data not shown). 401 
C3b deposition was minimal when strains were treated with C1q-depleted 402 
serum compared to normal serum. Supplementation of C1q-depleted serum with 403 
purified C1q (to physiological levels) restored C3b deposition (Fig. 5C).  These data 404 
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indicate that most of the C3b bound to SM surface resulted from activation of C1 405 
component of the classical pathway. Thus, covRSm inactivation impairs SM-surface 406 
binding of serum IgG antibodies and CRP, serum components that trigger the classical 407 
pathway of complement activation, a major pathway involved in C3b deposition on 408 
SM. 409 
 410 
C3b deposition on SM is affected by interaction with sucrose-derived EPS. 411 
SM accesses the bloodstream from oral niches, where it is exposed to dietary sucrose 412 
to synthesize EPS, including glucan. CovRSm inactivation in serotype c strains not only 413 
up-regulates genes for the synthesis of sucrose-derived glucan (gtfB, gtfC, gtfD), but 414 
genes encoding glucan-binding proteins (gbpB, gbpC) and EpsC (epsC), which are 415 
involved in surface binding to these polymers (7,8,10,11,43). Therefore, to address 416 
whether sucrose-derived EPS on SM surface influences on C3b deposition, we 417 
compared levels of C3b binding between parent and isogenic mutants of covRSm, 418 
gtfB/C/D, gbpC and epsC previously grown in media with different concentrations of 419 
sucrose, which were then harvested, washed and exposed to serum. As observed in 420 
Fig. 6A, parent and covRSm grown in the presence of sucrose showed reduced levels of 421 
C3b compared to the same strain grown in medium without sucrose. C3b deposition 422 
was more intensely reduced in the UAcov in the presence of sucrose. When grown in 423 
CDM supplemented with 0.1% sucrose, mean levels of C3b (MFI) on UAcov were 4-fold 424 
lower than in the parent UA159 (82.3 versus 326.4). In sucrose-free CDM, levels of C3b 425 
on UAcov were only 1.9-fold lower than C3b levels of parent UA159 (507.4 versus 426 
991.5). In BHI, UAcov showed a 4-fold reduction in C3b deposition, but in BHI with 427 
0.1% sucrose, the UAcov showed 9.4-fold reduction in C3b deposition compared to 428 
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parent strain (33.4 versus 315.4). Although C3b binding was higher on strains grown in 429 
sucrose-free CDM compared to BHI (Fig 6A), addition of 0.01% sucrose to CDM was 430 
sufficient to eliminate these differences. This result suggests trace amounts of sucrose 431 
in the complex BHI medium, although we can not rule out that unknown BHI 432 
components adsorbed to the SM surface could also influence on C3b deposition.  433 
Because sucrose-derived glucan are synthesized by GtfB, GtfC and GtfD, we 434 
further confirmed that deletion of multiple gtf genes (double gtfB/C and triple 435 
gtfB/C/D mutants) would eliminate the effect of previous exposure to sucrose on SM 436 
susceptibility to C3b deposition. GtfB synthesizes insoluble glucan (rich in α1-3 437 
linkages), while GtfC a mixture of insoluble and soluble (rich in α1-6 linkages) glucan, 438 
and GtfD synthesizes only soluble glucan (1). As expected, significant increases in C3b 439 
deposition were observed in the gtfB/C and gtfB/C/D mutants compared to parent 440 
strain MT8148 in all culture conditions (Kruskal-Wallis with post hoc Dunn’s test; 441 
p<0.05). Supplementation of growth medium with sucrose, did not significantly affect 442 
C3b deposition on these mutants (Fig. 6B). Therefore, sucrose-derived EPS impacts C3b 443 
deposition on SM surface. Of note, analyses of the effects of gtfB/C/D on C3b 444 
opsonization were performed with mutants previously obtained in strain MT8148, 445 
because gbpC inactivation affected C3b deposition on MT8148 in a similar fashion to 446 
that observed in UA159 (see below). 447 
Because levels of sucrose in the bloodstream seems to be minimal (46), we 448 
assessed whether the SM capacity to bind sucrose-derived EPS influences C3b 449 
deposition. Thus, levels of C3b were compared between the gbpC mutant (UAgbpC) 450 
and parent strain UA159 previously grown in the presence or absence of sucrose. As 451 
shown in Fig. 6C, deletion of gbpC promoted significant increase in C3b deposition 452 
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when compared to the parent strain, especially when strains were recovered from 453 
sucrose-containing medium: 0.1% sucrose BHI (mean 4.6-fold increase in C3b MFI) and 454 
0.1% sucrose CDM (mean 3.2-fold increase in C3b MFI) (Kruskal-Wallis with post hoc 455 
test, p<0.05). These results are compatible with the UAgbpC inability to bind EPS 456 
produced from sucrose (Fig. 3B; Fig. S2). Similar results were observed in the gbpC 457 
mutant obtained in strain MT8148 (data not shown). Influence of sucrose-derived 458 
products on C3b deposition was further analyzed in the epsC mutant. Previous growth 459 
of the epsC mutant in the presence of sucrose reduced C3b deposition (Fig. 6C), which 460 
is compatible with the finding that UAepsC retained some capacity to bind EPS (Fig. 461 
3B).  Thus, expression of proteins which bind sucrose-derived EPS significantly affects 462 
SM susceptibility to C3b deposition. Of note, the wild type strain MT8148 shows lower 463 
binding to C3b than UA159 strain (Fig. 6A,B), consistently with its higher capacity to 464 
interact with sucrose-derived EPS compared to UA159 (Fig. 3C).  465 
Finally, to confirm that reduced susceptibility of blood isolates to C3b 466 
deposition was promoted by sucrose-derived EPS, we compared levels of C3b 467 
deposition on the blood strains SA13 and SA18 grown in the four growth media. As 468 
reference, the oral strain 2VS1 (with reduced binding to sucrose-derived EPS; Fig. 3A) 469 
was also tested. As expected, levels of C3b deposition on SA13 and SA18 increased 470 
when strains were grown in sucrose-free CDM (Fig. 6D). Levels of C3b deposition on 471 
2VS1 were significantly higher than that observed in the blood strains in all growth 472 
conditions (Kruskal-Wallis; p<0.05), but addition of sucrose to media did not 473 
significantly affect C3b binding to this strain (Fig. 6D). Thus, low susceptibility of blood 474 
strains to C3b deposition is influenced by sucrose-derived EPS in a fashion similar to 475 
that observed in the covR mutant. 476 
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Sucrose-derived EPS influence on binding of serum IgG to the SM surface, 477 
and on frequencies of opsonophagocytosis and killing by human PMN. Because 478 
complement activation on SM was found to be strongly dependent on the classical 479 
pathway, we investigated whether changes in C3b deposition in SM promoted by 480 
previous growth in the presence of sucrose could be associated with reduced binding 481 
to serum IgG. As observed in Fig. 7A, levels of IgG bound to UA159 and UAcov were 482 
impaired when these strains were grown in medium added of sucrose. In addition, 483 
exposure to sucrose significantly reduced phagocytosis and killing by PMN, specially in 484 
UAcov (Fig. 7B,C). Consistently with flow cytometry analysis of phagocytosis (Fig. 7B), 485 
mean counts of extracellular UAcov in the supernatants of PMN analyzed in killing 486 
assays were 1.6 and 6.3-fold higher than UA159 extracellular counts, when strains 487 
were respectively  grown in CDM and CDM with 0.1% sucrose (data not shown). In 488 
addition, similar to UAcov, grow of the blood strains SA13 and SA18 in medium 489 
supplemented with sucrose impaired binding of serum IgG (Fig. 7D), reduced the 490 
frequency of phagocytosis (Fig. 7E) and increased resistance to killing by PMN (Fig. 7F). 491 
Differently, media supplementation with sucrose promoted limited effects on IgG 492 
binding and phagocytosis in 2VS1 (Fig. 7D, E). These results support the role of surface-493 
associated EPS on evasion to opsonophagocytosis and killing by PMN. 494 
Binding of serum IgG to SM surface and rates of serum-mediated phagocytosis 495 
were also assessed in mutants of CovRSm-repressed genes involved in the synthesis 496 
and/or interaction with EPS (Fig. 8). Significant increases in IgG binding to SM surface 497 
were promoted by inactivation of epsC, gbpC (Fig. 8A) and gtfB/C/D (Fig. 8C). 498 
Inactivation of lysM and wapE had modest effects on IgG binding (Fig. 8A), compatible 499 
with limited effects of these genes on binding to sucrose-derived EPS (Fig. 3B). 500 
 o
n











Increases in phagocytosis were also observed in epsC, gbpC and gtfB/C/D (Fig. 8B, D). 501 
As observed for C3b deposition, complementation of gbpC and epsC mutants restored 502 
levels of IgG binding and phagocytosis (Fig. 8A, B). These findings strengthen the 503 
influence of SM interactions with sucrose-derived EPS on strain susceptibilities to 504 
opsonic phagocytosis by human PMN. 505 
 506 
Inactivation of covRSm and of CovRSm-repressed gbpC and epsC affects 507 
survival of SM in human blood and systemic virulence. Because complement 508 
immunity is an important mechanism of blood clearance of streptococcal pathogens 509 
(28,30,47), we investigated the effects of inactivation of covRSm and downstream genes 510 
on ex vivo survival of SM in human blood. The UAcov mutant showed increased 511 
capacity to survive in human blood, which was completely restored in the UAcov+ 512 
complemented mutant (Fig. 9A). Consistent with the role of CovRSm as a direct 513 
repressor of gbpC and epsC, the UAgbpC and UAepsC mutants showed reduced 514 
survival in blood, when compared to parent and respective complemented mutants 515 
(Fig. 9B, C). To further confirm the effects of EPS on the increased ex vivo survival of 516 
UAcov in blood, assays were performed with strains grown in sucrose-free CDM and in 517 
CDM with 0.1% sucrose. As shown in Fig. 9D, differences in survival in blood between 518 
UAcov and UA159 were eliminated when strains were grown in CDM, whereas CDM 519 
supplementation with sucrose increased differences between UAcov and parent 520 
strains (Fig. 9E). Thus, sucrose-derived EPS are involved in the increased survival of 521 
UAcov in human blood. 522 
Comparisons of bacterial counts in the bloodstream of rats, confirmed 523 
findings of ex vivo survival in human blood for UAcov. As shown in Table 3, UAcov 524 
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mutant survives for longer periods and at higher counts in the rat bloodstream, when 525 
compared to parent or complemented strains. Two rats infected with UAcov died 526 
during the experiment, while no deaths occurred in the UA159-infected group. Higher 527 
SM counts were found in valves of UAcov-infected rats (cfu/ml; mean: 20,090 ± 528 
44,467; median: 40) compared to the valves of UA159-infected animals (mean: 1,352 ± 529 
2,723; median: 0), although differences between strains did not reach statistical 530 




The complement system plays multiple roles in elimination of 535 
microorganisms, both as part of the innate immune system and by augmenting 536 
antibody-mediated immunity (17,18). Reduced susceptibilities to C3b deposition found 537 
in SM blood strains (Fig. 1) indicate that evasion to complement immunity is important 538 
for systemic virulence of SM. In GAS, natural mutations in covRSpy were detected in 539 
strains involved in human infections, and inactivation of the TCS CovRSSpy enhanced 540 
strain virulence in murine models (48-50). Virulence genes repressed by CovRSpy 541 
include genes involved in complement evasion (e.g. has operon for hyaluronic acid 542 
capsule synthesis) (50-52), which are not present in the SM genomes (53,54). Reduced 543 
transcript levels of covRSm in blood isolates associated with increased transcription of 544 
CovRSm-repressed genes (gbpC, gbpB, epsC), suggests that diversity in covRSm activities 545 
influences on SM strain capacity to survive in the bloodstream.  546 
In GAS and GBS, CovRSSpy/Sag regulons show strain-specificity (55,56).The 547 
CovRSm regulon was assessed in the serotype c strain UA159 (8,11), but its diversity 548 
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remains to be investigated in strains associated with systemic infections. SM serotype 549 
c was detected with higher frequencies in SM-positive specimens of heart valve and 550 
atheromatous plaque from patients subjected to cardiovascular surgeries (30.3 and 551 
65.5% of specimens respectively), compared to serotype k (detected in 9.1 and 25% of 552 
these specimens, respectively) (14), previously implicated in systemic infections (57). 553 
Interestingly, 77% of serotype k-positive specimens were also positive for serotype c 554 
(41), suggesting synergy of SM serotypes for systemic virulence. Systemic virulence of 555 
serotype k is associated with expression of the collagen-binding proteins Cnm and 556 
Cbm, which are involved in SM capacity to invade endothelial cells in vitro (40,58-60) 557 
and to form vegetations on injured heart valves in a rat model of infective endocarditis 558 
(40). However, serotype c strains rarely harbour these genes (19) and there is no 559 
report that CovRSm regulates cnm or cbm.  560 
A major function of complement immunity against Gram-positive bacteria is 561 
to covalent bind C3b/iC3b opsonins on the bacterial surface through the activity of C3-562 
convertases on C3 (17,18). C3-convertases result from proteolytic cascades initiated by 563 
different mechanisms, known as the classical, mannan-binding lectin and alternative 564 
pathways (17). Functions of each pathway in complement immunity against 565 
streptococci seem to be species-specific (27,28,30,45), and are usually circumvented 566 
by multiple evasion mechanisms (41,61,62). Here, we show that the classical pathway 567 
plays a major role in complement deposition on SM (Fig. 5C), which is consistent with 568 
reduced binding to IgG antibodies to UAcov (Fig. 5A). Because C1q is activated through 569 
its binding to IgG on bacterial surface, assessing individual roles of complement and 570 
IgG to S. mutans opsonization is difficult. In addition, although SM seems to not have 571 
prototypical CRP-ligands (63), covRSm inactivation also reduced binding to CRP (Fig. 5B). 572 
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CRP levels increase in the bloodstream of subjects with biofilm-dependent oral 573 
diseases, e.g. gingivitis and periodontitis (64), thus the role of acute-phase proteins on 574 
SM blood clearance need to be investigated. 575 
The major known role of CovRSm in SM biology is to regulate the expression of 576 
secreted enzymes for the synthesis of EPS from sucrose, and cell surface components 577 
involved in interaction with EPS (5,6,10,11). Some of these genes, e.g. gtfBC, ftf and 578 
wapE, are controlled by a complex regulatory circuit (11,65-67), which might explain 579 
the lack of associations between gtfB/C transcription and profiles of covRSm expression 580 
among the tested strains (Fig. 2). Because secreted GtfB/C are stable in saliva and bind 581 
to several oral bacteria (2), strains with increased binding to EPS could benefit from 582 
Gtf-producing members of the same ecological niche. Thus, increased capacity to bind 583 
EPS would be more significant for systemic virulence than the ability to produce Gtfs 584 
itself. In the serotype c strain V403, deletion of multiple genes required for the 585 
synthesis of EPS from sucrose (gtfB, gtfC, ftf), increased SM phagocytosis by human 586 
granulocytes and reduced virulence in an animal model of infectious endocarditis (68). 587 
Consistently, our gtfB/C and gtfB/C/D mutants showed high susceptibility to C3b-588 
opsonization even when grown in the presence of sucrose (Fig. 6). However, 589 
production of sucrose-derived EPS only impaired C3b deposition in strains capable to 590 
bind these polymers; the gbpC mutant was susceptible to C3b deposition even when 591 
grown in the presence of sucrose (Fig. 6). Thus, expression of gbpC, and perhaps other 592 
glucan-binding proteins upregulated in blood isolates, e.g. GbpB (Fig. 2), might be 593 
critical for EPS-mediated complement evasion.  594 
Increased binding of the gbpC mutant to serum IgG (Fig. 6), further indicates 595 
that surface EPS may impair antibody-mediated activation of complement in a way 596 
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analogous to capsules of S. pneumoniae (45,47,69). Besides GbpC, EpsC, showed 597 
prominent influence in complement opsonization (Fig. 6,8). In Gram-positive bacteria 598 
EpsC is required for the production of UDP-ManNAc, an intermediate for the synthesis 599 
of EPS, which is also required for the attachment of teichoic acids to the cell wall (70-600 
73). The epsC mutant retained some degree of binding to sucrose-derived EPS (Fig. 3B), 601 
which might explain, at least in part, the remaining influence of sucrose on binding of 602 
C3b to this mutant (Fig. 6). Alternatively, EpsC could also affect sucrose-independent 603 
mechanisms of SM evasion to complement immunity. Functional analyses of EpsC 604 
might shed new light on its roles in complement susceptibility.  605 
Although the effects of covR deletion on C3b opsonization were more clearly 606 
observed when strains were grown in sucrose-containing media, reductions in levels of 607 
C3b binding to UAcov were still observed in sucrose-free CDM (Fig. 6), which suggests 608 
that CovRSm regulates additional functions of complement evasion. Lower levels of C3b 609 
binding to blood strains grown in sucrose-free CDM (especially in SA13; Fig. 6), account 610 
for the hypothesis that SM strains apply multiple mechanisms of complement evasion. 611 
In GAS strains, CovRSpy plays multiple roles in complement evasion besides regulating 612 
capsule production (50,52,74). Studies are in course to identify additional factors 613 
affecting SM susceptibility to complement immunity.  614 
The increased persistence of UAcov in human blood mediated by sucrose-615 
derived EPS (Fig. 9) and its ability to cause bacteremia in rats (Table 3), further 616 
strengthen the role of CovRSm in systemic virulence. Reduced C3b/IgG-opsonization of 617 
UAcov is, at least in part, explained by up-regulation of epsC and gbpC, because 618 
inactivation of these genes reduced survival in human blood (Fig. 9A,B). Different from 619 
this study, no reduction in survival in the bloodstream of rats was observed in the gbpC 620 
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mutant (C1) obtained in MT8148, compared to a streptomycin-resistant MT8148 621 
variant (MT8148R) (75). Although we found that C1 has increased susceptibility to C3b 622 
deposition compared to MT8148 parent strain (data not shown), C3b deposition in the 623 
MT8148R variant is unknown. As shown in this study, differences in growth media can 624 
affect SM susceptibility to complement opsonization. Furthermore, bacterial 625 
aggregation mediated by blood components could affect bacterial counts in blood 626 
suspensions. UAcov shows increased aggregation in blood compared to UA159 (data 627 
not shown), which could explain the initial reductions in UAcov counts in the ex vivo 628 
assays, although bacterial loads were normalized by initial blood counts (Fig. 9). 629 
Increased aggregation of UAcov could occur in the rat bloodstream, thus survival rates 630 
of UAcov (Table 3) might be underestimated. 631 
Differences in complement activation on SM between the human and rat 632 
blood may also exist. SM is an exclusive species of humans, thus levels and epitope 633 
specificities of IgG antibodies to SM may differ between human and rat sera. Further 634 
differences exist in production and structure of CRP between rats and humans (76). In 635 
addition, CR1, shown to be important for SM opsonophagocytosis, is also involved in 636 
blood clearance by human erythrocytes through immune adherence (77). Because 637 
rodent erythrocytes do not express CR1 (77), a more complete analysis of the influence 638 
of C3b deposition on blood clearance of SM would require animal models designed to 639 
assess CR1-mediated immune adherence (78). Apart from the limitations of our model, 640 
significant increases were detected in viable counts of UAcov in the rat bloodstream, 641 
compared to UA159 (Table 3). At 6 h post-infection, there was 6.3-fold higher counts 642 
of UAcov mutant (detected in 85.7% of the animals) compared to parent strain 643 
(detected in 57.1% of animals). Although UAcov counts in heart valves were higher 644 
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compared to UA159 counts, these differences did not reach significance. Because only 645 
the numbers of viable bacteria were assessed, we cannot exclude the possibility that 646 
increased differences on tissue infection might have been observed between strains if 647 
total levels of bacteria in heart valve specimens were measured using culture-648 
independent methods. In addition, survival of UAcov in the rat bloodstream would 649 
likely increase if strains were previously grown in medium added of 0.1% sucrose. 650 
Therefore, studies are required to improve in vivo models for assessing the influence of 651 
complement evasion on systemic virulence of SM. 652 
In summary, this study provides evidence that systemic virulence of SM 653 
strains involves reduced susceptibility to complement-mediated opsonization. Roles of 654 
CovRSm in resistance to complement immunity involves the regulation of SM capacity 655 
to interact EPS, which in turn affects complement activation. Two CovRSm-repressed 656 
genes, gbpC and epsC were identified as playing important roles in resistance to 657 
complement immunity and survival in blood, as revealed by transcriptional profiles of 658 
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FIGURE LEGENDS 960 
Fig. 1. A. Box plot comparisons of C3b deposition between S. mutans (SM) strains 961 
isolated from blood samples and from the oral cavity. C3b bound to serum-treated 962 
strains was probed with anti-C3 antibody conjugated with FITC for flow cytometry 963 
analysis. A) Levels of C3b bound to SM strains were expressed as geometric Mean 964 
Fluorescence Intensity (MFI). B) Fluorescence Index (FI) values were obtained by 965 
multiplying the percentage of C3b-positive cells by MFI for C3b. MFI and FI data are 966 
means of three independent experiments. Asterisks indicate significant differences 967 
between groups (Mann-Whitney U-test; p< 0.05).  968 
 969 
Fig. 2. RT-qPCR comparisons of transcript levels of covRSm and CovRSm-regulated 970 
genes (lysM, wapE, epsC, gbpC, gbpB, gtfB, gtfC) between blood (n=4) and oral (n=5) 971 
strains of S. mutans. Gene gtfD, which is not regulated by CovRSm was tested as a 972 
control. Asterisks indicate significant differences in mean levels of  transcripts between 973 
groups (ANOVA post hoc Tukey´s  test;  p< 0.05).  974 
 975 
Fig. 3. Comparisons of S. mutans capacities to aggregate in the presence of sucrose-976 
derived EPS.  Strains were incubated in BHI supplemented with 0.1% sucrose during 24 977 
h for visual analysis of clump formation. Intensities of cell aggregation were 978 
determined by a blind examiner and indicated below the respective images.  A) 979 
Comparisons between blood and oral strains. B) Comparisons between parent strain 980 
UA159 with the respective knockout mutants. C) Comparisons of parent strain MT8148 981 















Fig. 4. Comparisons of C3b deposition, opsonophagocytosis and killing by PMN 984 
between covR mutant (UAcov) with parent (UA159) and complemented strains (+). A) 985 
Intensities of C3b deposition (MFI) were determined by flow cytometry in strains 986 
treated with a reference serum or pools of sera obtained from six volunteers. B) 987 
Percentages of PMN with associated bacteria were assessed after 5 min of PMN 988 
exposure to FITC-labeled bacteria in the presence of 20% serum. Untreated PMN and 989 
PMN treated with MAbs to block CR1 (CD35), CR3 (CD11b/CD18), FcɤRII (CD32) and/or 990 
FcɤRIII (CD16) receptors were tested. C) Percentages of intracellular survival in PMN 991 
after 10 min of incubation with preopsonized bacteria were calculated in relation to 992 
bacterial counts of no PMN control samples. Columns represent means of three 993 
independent experiments. Bars indicate standard deviations. Asterisks indicate 994 
significant differences in relation to UA159 within the same condition (Kruskal-Wallis 995 
with post hoc Dunn’s test ; p< 0.05).  996 
 997 
Fig. 5. Binding of serum IgG, CRP and C3b to S. mutans strains in the presence of 998 
serum. A,B) Strains were treated with 20% human serum and levels of surface IgG or 999 
CRP determined by flow cytometry (MFI). S. pneumoniae strains D39 and TIGR4 were 1000 
used as control for CRP binding. C) Levels of C3b binding were measured after bacterial 1001 
treatment with a reference serum, serum depleted of C1q (C1q-) or C1q- serum 1002 
supplemented with purified C1q (C1q+). Columns represent means of three 1003 
independent experiments; bars represent  standard deviations. Strains were compared 1004 
using Kruskal-Wallis with post hoc Dunn’s test. Asterisks indicate significant differences 1005 















Fig. 6. Effects of previous growth in medium supplemented with sucrose in strain 1008 
susceptibilities to C3b deposition. Strains grown in BHI or CDM supplemented or not 1009 
with 0.01 or 0.1% sucrose were harvested, washed with PBS and treated with human 1010 
serum for C3b deposition. Columns represent means of MFI for C3b determined by 1011 
flow cytometry in three independent experiments. Bars represent standard deviations. 1012 
Asterisks indicate significant differences between groups (Kruskal-Wallis with post hoc 1013 
Dunn’s test: * p< 0.05).  1014 
 1015 
Fig. 7. Effects of previous growth of S. mutans strains in medium supplemented with 1016 
sucrose in binding to serum IgG, in susceptibility to phagocytosis by PMN and in killing 1017 
by PMN. A,D) Strains grown in BHI or CDM supplemented or not with 0.01 or 0.1% 1018 
sucrose were harvested, washed with PBS and treated with human serum for IgG 1019 
binding. Levels of IgG binding were determined by flow cytometry and expressed as 1020 
MFI. B,E) FITC-labeled strains grown in different media were incubated with PMN 1021 
isolated from human peripheral blood in the presence of 20% serum during 5 min. C, F) 1022 
Strains grown in CDM supplemented or not with 0.1% sucrose were preopsonized and 1023 
incubated with PMN (10 min). Percentages of intracellular survival were calculated in 1024 
relation to viable counts determined in the no PMN control samples. Columns 1025 
represent means of three independent experiments. Bars indicate standard deviations. 1026 
Asterisks indicate significant differences in comparison to parent strain (Kruskal-Wallis 1027 
with post hoc  Dunn’ test ; * p<0.05).  1028 
 1029 
Fig. 8. Comparisons of binging to serum IgG (A,C) and of phagocytosis by human PMN 1030 
(B, D) between mutants of genes regulated by CovRSm. Mutant (gray columns) or 1031 
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complemented (dashed columns) strains were compared with the respective parent 1032 
strain (UA159 or MT8148). Columns represent means of three independent 1033 
experiments; bars indicate standard deviations. Asterisks indicate significant 1034 
differences in relation to parent strain (Kruskal-Wallis with post hoc  Dunn’s test ; * 1035 
p<0.05).  1036 
 1037 
Fig. 9. Ex vivo viability in human blood. Numbers of viable bacteria (log cfu/ml) were 1038 
expressed in relation to initial counts of blood suspensions (time 0). A, B, C) Strains 1039 
were grown in BHI, D) CDM or E) CDM supplemented with 0.1% sucrose. Data 1040 
represent means of triplicate of one representative experiment. Bars indicate standard 1041 
deviations. Differences in relation to parent strain at each time-point were tested by 1042 
Kruskal-Wallis with post hoc Dunn’s test (*p<0.05).  1043 
 1044 
TABLE FOOTNOTES 1045 
Table 3. *Significant differences in relation to parent strain at the same time period 1046 
(Kruskal-Wallis with post hoc Dunn’s test; p < 0.05). 
a
Number of rats with recovered 1047 
bacteria are indicated within parentheses. 1048 
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UA159  UAcov 
+ + + + + 
MT8148 gbpC gtfBC gtfBCD 
+ + + 
 _  _  _ 
+ + + +  
UA159 wapE lysM epsC gbpC 
 _  _ 
Oral isolates 
SA13 SA15 SA16 8ID3 11SSST2 SA18 
Blood isolates 
2VS1 11A1 
+ + + + + + +  
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CR1 CR3 CR1 + CR3 FcγRII   FcγRIII FcγRII + 
FcγRIII 
CR1 + CR3 
























































































































































































































































































































































































































































































































































































































































































































































M 8    fBC   gtfB   
 o
n





























































































































































































































































































Taďle ϭ.  StraiŶs used iŶ this study. 
 
 
StraiŶ  ReleǀaŶt ĐharaĐteristiĐs SourĐe or refereŶĐe
UAϭϱϵ  Oral isolate, Đaries-affeĐted Đhild; erŵs, speĐs, kaŶs ATCC 
UAĐoǀR ∆ĐoǀR::Erŵr ;ϭϯͿ 
UAǁapE ∆ǁapE::Erŵr ;ϭϭͿ 
UAlysM ∆lysM::Erŵr ;ϭϭͿ 
UAepsC ∆epsC::Erŵr ;ϭϭͿ 
UAgďpC ∆gďpC::Erŵr This study
UAĐoǀR+     r  ∆ĐoǀR::Erŵr; pDLϮϳϴ::SMU.ϭ9Ϯϰ; SpeĐr ;ϭϯͿ 
UAǁapE+ ∆ǁapE::Erŵr; pDLϮϳϴ::SMU.ϭϬ9ϭ; SpeĐr ;ϭϭͿ 
UAlysM+ ∆lysM::Erŵr; pDLϮϳϴ::SMU.ϮϭϰϳĐ; SpeĐr ;ϭϭͿ 
UAepsC+   ∆epsC::Erŵr; pDLϮϳϴ::SMU.ϭϰϯϳĐ; SpeĐr ;ϭϭͿ 
UAgďpC+ ∆gďpC::Erŵr; pDLϮϳϴ::SMU.ϭϯ9ϲ; SpeĐr This study
MTϴϭϰϴ Oral isolate; healthy JapaŶese Đhild ;ϮϭͿ 
Cϭ ∆gďpC::KaŶr, ŵutaŶt of MTϴϭϰϴ ;ϮϭͿ 
Sϱ ∆gtfBC::Erŵr, douďle ŵutaŶt of MTϴϭϰϴ ;ϮϬͿ 
BCϳs ∆gtfD::Erŵr, ∆gtfBC::KaŶr, triple ŵutaŶt of MTϴϭϰϴ ;ϮϬͿ 
ϮSTϭ Oral Isolate, Đaries-affeĐted Đhild ;ϮϮͿ 
ϮVSϭ Oral Isolate, Đaries-affeĐted Đhild ;ϮϮͿ 
ϯSNϭ Oral Isolate, Đaries-free Đhild ;ϮϮͿ 
ϰSMϭ Oral Isolate, Đaries-free Đhild ;ϮϮͿ 
ϰVFϭ Oral Isolate, Đaries-affeĐted Đhild ;ϮϮͿ 
ϱSMϯ Oral Isolate, Đaries-free Đhild ;ϮϮͿ 
ϴIDϯ Oral Isolate, Đaries-free Đhild ;ϮϮͿ 
ϭϭAϭ Oral Isolate, Đaries-free Đhild ;ϮϮͿ 
ϭϭSSSTϮ Oral Isolate, Đaries-free Đhild ;ϮϮͿ 
ϭϭVSϭ Oral Isolate, Đaries-free Đhild ;ϮϮͿ 
ϭϱJPϯ Oral Isolate, Đaries-free Đhild ;ϮϮͿ 
ϭϱVFϮ Oral Isolate, Đaries-affeĐted Đhild ;ϮϮͿ 
SAϭϮ Blood,  iŶfeĐtiǀe eŶdoĐarditis ;ϭϵͿ 
SAϭϯ Blood, ďaĐtereŵia ;ϭϵͿ 
SAϭϰ Blood, iŶfeĐtiǀe eŶdoĐarditis ;ϭϵͿ 
SAϭϱ Blood, ďaĐtereŵia ;ϭϵͿ 
SAϭϲ Blood, iŶfeĐtiǀe eŶdoĐarditis ;ϭϵͿ 
SAϭϳ Blood, ďaĐtereŵia ;ϭϵͿ 
SAϭϴ Blood, iŶfeĐtiǀe eŶdoĐarditis ;ϭϵͿ 
Dϯϵ StreptoĐoĐĐus pŶeuŵoŶiae  serotype Ϯ ;NCTC ϳϰϲϲͿ NCTC 
TIGRϰ StreptoĐoĐĐus pŶeuŵoŶiae serotype ϰ ;ATCC BAA-ϯϯϰͿ ATCC 
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Taďle Ϯ. OligoŶuĐleotides used iŶ this study.  
 
Naŵe  SeƋueŶĐe ;ϱ’ – ϯ’Ϳa  
 







ϵϵϴ ďp; aŵpliĐoŶ ĐoŶtaiŶiŶg the 







ϰϳϯ ďp; ϯϮϯ ďp upstƌeaŵ to ϭϱϬ ďp 







ϯϴϳ ďp; ϭ,ϲϬϱ ďp upstƌeaŵ to ϮϰϬ 








Ϯ,ϭϯϵ ďp; aŵpliĐoŶ ĐoŶtaiŶiŶg gbpC 
eŶĐodiŶg ƌegioŶ foƌ ŵutaŶt 
ĐoŵpleŵeŶtatioŶ.  
a UŶdeƌliŶed seƋueŶĐes iŶdiĐate ƌestƌiĐtioŶ eŶzyŵe liŶkeƌs. 
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Taďle ϯ. BaĐterial ĐouŶts ;Đfu/ŵlͿ reĐoǀered froŵ ďlood of rats ;Ŷ=ϳͿ. 
 
IŶfeĐted straiŶ MeaŶ Đfu/ŵl of ďlood ± SD ;
aͿ at differeŶt  post-iŶfeĐtioŶ periods  
ϭ h ϯ h ϲ h Ϯϰ h ϳ days 
UAϭϱϵ  ϭ,ϲϮϳ ±  ϭ,ϬϮϵ ;ϳͿ 
Ϯϰϳ ± ϭϯϱ 
;ϳͿ 






UAĐoǀ ϭ,ϳϲϳ ± ϭ,Ϭϱϯ ;ϳͿ 
ϭϵϰ ±  ϭϰϳ 
;ϳͿ 




ϭϲ ± ϯϲ * 
;ϱͿ 
UAĐoǀ+ Ϯ,ϱϬϭ ± Ϯ,ϯϬϵ ;ϳͿ 
ϭϬϰ ± ϲϰ * 
;ϳͿ 
ϭϲ ± ϭϱ 
;ϰͿ 




*SigŶifiĐaŶt differeŶĐes iŶ relatioŶ to pareŶt straiŶ at the saŵe tiŵe period ;Kruskal-Wallis ǁith post hoc 
DuŶŶ’s test; p < Ϭ.ϬϱͿ. 
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